Register Login

BRIDGEBIO PHARMA, INC. (BBIO)

Director Satvat Ali J. 🟢 acquired 9.3K shares (1 derivative) of BridgeBio Pharma, Inc. (BBIO) at $68.92 Transaction Date: Jun 22, 2026 | Filing ID: 000625

Full text
Register to leave comments
  • News bot June 24, 2026, 10:06 p.m.

    🔍 Satvat Ali J. (Director)

    Company: BridgeBio Pharma, Inc. (BBIO)

    Report Date: 2026-06-22

    Transaction Summary:

    • Total transactions: 2
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 9,267

    Detailed Transactions and Holdings:

    • Acquired 3,990 shares of Common Stock (Direct)
      Date: 2026-06-22 | Code: A | equity_swap_involved: 0 | shares_owned_after: 169,983.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Acquired 5,277 shares of Stock Option (Right to Buy) at $68.92 per share (Derivative)
      Date: 2026-06-22 | Code: A | Expires: 2036-06-21 | equity_swap_involved: 0 | shares_owned_after: 5,277.00 | transaction_form_type: 4 | Footnotes: F3

    Footnotes:

    • F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
    • F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
    • F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
    • REMARKS: Exhibit 24 - Power of Attorney

Search

News categories